There is also interest in CLDN4 and CLDN9 as markers of drug resistance; for instance, CLDN9 upregulation in breast cancer was associated with chemotherapy failure (94), suggesting that targeting CLDN9 or its pathway could resensitize tumors to treatment. The gene discussed is CLDN4; the disease is breast carcinoma.